You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The researchers, from various institutions in China, said they hope their data will contribute to the completion of the international Human Cell Atlas project.
The Solna, Sweden-based company is currently expanding from offering in situ sequencing services to selling kits.
The company plans to offer four new products by the end of the year, including four targeted transcriptomic panels and IHC compatibility for Visium.
In Science this week: comprehensive cellular map of the human thymus, evidence of admixture between the ancestors of Neanderthals and Denisovan and a 'superarchaic' population.
Though 10x will phase out its linked reads technology, it plans to introduce targeted RNA-seq for Chromium and FFPE sample compatibility for Visium.
The single-cell analysis and spatial genomics company reported $75.3 million in Q4 revenues. Full year revenues grew 68 percent to $245.9 million.
10x Genomics sued Harvard University and 1CellBio, a competing single-cell technology firm, in 2018 over licenses for patents granted to both companies.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
Illumina said the NextSeq 2000 and NextSeq 1000 reduce run costs by up to 50 percent, compared to the NextSeq 550 model, while increasing the data output.
On the second day of the conference, updates came not just from the publicly traded industry giants but also privately held firms of interest, such as Caris and GenapSys.
Bloomberg reports that vaccine developers won't have to conduct large trials of updated vaccines or vaccine boosters aimed at new viral variants.
The SARS-CoV-2 variant uncovered in California may be more transmissible and partially evade vaccine-induced antibody response, the Los Angeles Times reports.
Francis deSouza, the CEO of Illumina, calls for a global SARS-CoV-2 genomics surveillance network, according to the Financial Times.
In PNAS this week: immunotherapy for hard-to-treat breast cancers, effects of oncogenic histone H3K36M mutations, and more.